X4 Pharmaceuticals, Inc (XFOR) Share-based Payment Arrangement, Expense USD 2017 - 2024

Historical data

Taxonomy & unit: us-gaap: USD
Description: Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary: X4 Pharmaceuticals, Inc quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2017 to 2024.
X4 Pharmaceuticals, Inc Share-based Payment Arrangement, Expense for the quarter ending March 31, 2024 was $1.74 M, a 5.71% increase year-over-year.
X4 Pharmaceuticals, Inc Share-based Payment Arrangement, Expense for the twelve months ending March 31, 2024 was $8.78 M, a 63.1% increase year-over-year.
X4 Pharmaceuticals, Inc annual Share-based Payment Arrangement, Expense for 2023 was $8.69 M, a 67.1% increase from 2022.
X4 Pharmaceuticals, Inc annual Share-based Payment Arrangement, Expense for 2022 was $5.2 M, a 15.9% decline from 2021.
X4 Pharmaceuticals, Inc annual Share-based Payment Arrangement, Expense for 2021 was $6.18 M, a 13.9% increase from 2020.

Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)

Share-based Payment Arrangement, Expense, Quarterly (USD)

Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)

Period	TTM Value	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed
Q1 2024	$8.78 M	$1.74 M	+$94 K	+5.71%	Jan 1, 2024	Mar 31, 2024	10-Q	2024-05-07
Q4 2023	$8.69 M	$2.54 M	+$1.43 M	+129%	Oct 1, 2023	Dec 31, 2023	10-K	2024-03-21
Q3 2023	$7.26 M	$2.36 M	+$1.25 M	+113%	Jul 1, 2023	Sep 30, 2023	10-Q	2023-11-09
Q2 2023	$6.01 M	$2.14 M	+$620 K	+40.7%	Apr 1, 2023	Jun 30, 2023	10-Q	2023-08-10
Q1 2023	$5.39 M	$1.65 M	+$186 K	+12.7%	Jan 1, 2023	Mar 31, 2023	10-Q	2024-05-07
Q4 2022	$5.2 M	$1.11 M	-$502 K	-31.2%	Oct 1, 2022	Dec 31, 2022	10-K	2024-03-21
Q3 2022	$5.7 M	$1.11 M	-$405 K	-26.7%	Jul 1, 2022	Sep 30, 2022	10-Q	2023-11-09
Q2 2022	$6.11 M	$1.52 M	-$275 K	-15.3%	Apr 1, 2022	Jun 30, 2022	10-Q	2023-08-10
Q1 2022	$6.38 M	$1.46 M	+$201 K	+16%	Jan 1, 2022	Mar 31, 2022	10-Q	2023-05-04
Q4 2021	$6.18 M	$1.61 M	+$211 K	+15.1%	Oct 1, 2021	Dec 31, 2021	10-K	2024-03-21
Q3 2021	$5.97 M	$1.52 M	-$728 K	-32.4%	Jul 1, 2021	Sep 30, 2021	10-Q	2022-11-03
Q2 2021	$6.7 M	$1.8 M	+$624 K	+53.2%	Apr 1, 2021	Jun 30, 2021	10-Q	2022-08-04
Q1 2021	$6.07 M	$1.26 M	+$645 K	+105%	Jan 1, 2021	Mar 31, 2021	10-Q	2022-05-12
Q4 2020	$5.43 M	$1.4 M	+$734 K	+111%	Oct 1, 2020	Dec 31, 2020	10-K	2023-03-21
Q3 2020	$4.69 M	$2.24 M	+$1.55 M	+225%	Jul 1, 2020	Sep 30, 2020	10-Q	2021-11-04
Q2 2020	$3.14 M	$1.17 M	+$740 K	+171%	Apr 1, 2020	Jun 30, 2020	10-Q	2021-08-03
Q1 2020	$2.4 M	$613 K	+$351 K	+134%	Jan 1, 2020	Mar 31, 2020	10-Q	2021-05-06
Q4 2019	$2.05 M	$664 K	+$376 K	+131%	Oct 1, 2019	Dec 31, 2019	10-K	2022-03-17
Q3 2019	$1.67 M	$691 K	+$493 K	+249%	Jul 1, 2019	Sep 30, 2019	10-Q	2020-11-05
Q2 2019	$1.18 M	$433 K	+$288 K	+199%	Apr 1, 2019	Jun 30, 2019	10-Q	2020-08-04
Q1 2019	$893 K	$262 K	+$134 K	+105%	Jan 1, 2019	Mar 31, 2019	10-Q	2020-05-07
Q4 2018	$759 K	$288 K	+$423 K		Oct 1, 2018	Dec 31, 2018	10-K	2021-03-19
Q3 2018	$336 K	$198 K	-$75 K	-27.5%	Jul 1, 2018	Sep 30, 2018	10-Q	2019-11-07
Q2 2018	$411 K	$145 K	-$27 K	-15.7%	Apr 1, 2018	Jun 30, 2018	10-Q	2019-08-07
Q1 2018	$438 K	$128 K	-$54 K	-29.7%	Jan 1, 2018	Mar 31, 2018	10-Q	2019-05-15
Q4 2017	$492 K	-$135 K			Oct 1, 2017	Dec 31, 2017	10-K	2020-03-12
Q3 2017		$273 K			Jul 1, 2017	Sep 30, 2017	10-Q	2018-11-09
Q2 2017		$172 K			Apr 1, 2017	Jun 30, 2017	10-Q	2018-08-13
Q1 2017		$182 K			Jan 1, 2017	Mar 31, 2017	10-Q	2018-05-10

* An asterisk sign (*) next to the value indicates that the value is likely invalid.